MYNZ
Mainz Biomed N.V.
1.0000
-0.0200-1.96%
Dec 16, 4:00:01 PM EST

Upcoming Earnings 

Report date
-/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap
8.58M
P/E (TTM)
-
Basic EPS (TTM)
-5.28
Dividend Yield
0%

About 

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.

CEO
Mr. Guido Baechler
IPO
11/5/2021
Employees
19
Sector
Healthcare
Industry
Diagnostics & Research